Copyright © 2006 American Medical Association. All rights reserved. From: Improved Adherence and Less Toxicity With Rifampin vs Isoniazid for Treatment of Latent TuberculosisA Retrospective Study Arch Intern Med. 2006;166(17):1863-1870. doi:10.1001/archinte.166.17.1863 Figure Legend: Flow diagram of the study population. LTBI indicates latent tuberculosis infection; 4-RIF, 4-month regimen of rifampin therapy; and 9-INH, 9-month regimen of isoniazid therapy. Date of download: 10/27/2017 Copyright © 2006 American Medical Association. All rights reserved.

Copyright © 2006 American Medical Association. All rights reserved. From: Improved Adherence and Less Toxicity With Rifampin vs Isoniazid for Treatment of Latent TuberculosisA Retrospective Study Arch Intern Med. 2006;166(17):1863-1870. doi:10.1001/archinte.166.17.1863 Figure Legend: Percentage of patients completing treatment by month for isoniazid and rifampin groups. Error bars represent 95% confidence intervals. 4-RIF indicates 4-month regimen of rifampin therapy; and 9-INH, 9-month regimen of isoniazid therapy. Date of download: 10/27/2017 Copyright © 2006 American Medical Association. All rights reserved.